Last updated: July 28, 2026
ecutive summary
Janssen Pharmaceutica N.V. v. Mylan Pharmaceuticals Inc. (1:05-cv-00371) is a pre-2010 Hatch-Waxman patent infringement dispute tied to a Janssen branded product and a Mylan ANDA challenger. The record needed to produce a complete, accurate litigation summary and enforceability/validity strength analysis (asserted patents, claims, disposition, settlement terms, and any Federal Circuit outcomes) is not available in the provided context, so no reliable case-specific conclusions can be issued.
Janssen v. Mylan 1:05-cv-00371 litigation summary and analysis
No complete, case-specific litigation dataset (docket history, asserted patents and claims, claim construction rulings, dispositive motions, judgment/sanctions, settlement status, and appellate outcomes) is present to support an accurate summary.
What patents did Janssen assert in 1:05-cv-00371 against Mylan?
A correct answer requires the asserted patent numbers, listed claims, and the mapping to the ANDA product. None of that information is included in the prompt.
Which Orange Book patents were at issue?
The Orange Book listing details for the relevant Janssen drug, including expiration and regulatory exclusivity context, are not provided.
Were the asserted patents formulation, method-of-use, or manufacturing patents?
No asserted-patent types or independent-claim themes are provided.
What was Mylan’s ANDA and Paragraph IV posture in 1:05-cv-00371?
A valid summary must specify the ANDA number, filing date, Paragraph IV certifications (I, II, III, IV), and any carve-outs. These facts are not provided.
What FDA product labeling did Mylan seek to match?
No FDA labeling or indication/potency/strength details are provided.
What did the court rule in Janssen Pharmaceutica N.V. v. Mylan (1:05-cv-00371)?
A complete litigation analysis needs the procedural disposition: complaint filing date, motion-to-dismiss posture, claim construction, infringement/validity outcomes, final judgment, and any post-judgment motions. Those facts are not included.
Did the court grant summary judgment on infringement or invalidity?
No decision text, order docket entries, or dates are provided.
Were there Markman (claim construction) rulings?
No claim construction record is provided.
How strong were Janssen’s patents in 1:05-cv-00371 based on the court’s reasoning?
A strength assessment must tie specific legal findings (anticipation/obviousness, indefiniteness, written description/enablement, non-infringement defenses) to each asserted claim. No rulings are provided.
What were the main validity challenges raised by Mylan?
No invalidity arguments or cited references are provided.
What was Mylan’s non-infringement theory?
No non-infringement claim element-by-element analysis is provided.
Was there a settlement, consent judgment, or dismissal with prejudice in 1:05-cv-00371?
Settlement terms, effective date, market entry commitment, and any license scope are required for a real commercial and regulatory impact analysis. No settlement or dismissal data is included.
Did any FCA or licensing agreement run alongside the settlement?
No licensing or related agreements are provided.
When did exclusivity and patent expiration open generic entry risk from the 1:05-cv-00371 dispute?
A timeline requires the asserted patents’ expiration dates and any regulatory exclusivities (NCE, 5-year, 3-year, pediatric, exclusivity for formulations/changes). None are provided.
When does the listed Janssen patent estate lose exclusivity for the implicated indications/dosage forms?
No Orange Book dates are provided.
How does 1:05-cv-00371 affect biosimilar or generic competition for the same drug?
To evaluate competitive impact, the drug, indication, dosage form, and market context are needed. None are provided.
What generic entry risks existed for Mylan after 1:05-cv-00371?
A risk analysis depends on the final outcome and any remaining patents. No post-judgment patent landscape is provided.
What other companies joined similar challenges against the same Janssen product?
A comparative landscape requires other ANDA litigations and related case numbers. None are provided.
Key Takeaways
No case-specific litigation summary or enforceability analysis can be produced from the provided input.
FAQs
- What does case docket number 1:05-cv-00371 indicate about Hatch-Waxman posture?
- How do Paragraph IV certifications typically shape the early-stage schedule in district court?
- What claim construction factors most often drive summary judgment in ANDA patent cases?
- How do settlement terms usually translate into agreed-upon market entry dates?
- How can a final district court judgment influence later ANDA litigation against the same Orange Book listing?
References
No sources were cited because no case-specific facts, docket records, or court documents were provided in the prompt.
